Static Chart Arrowhead Pharmaceuticals, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 15:56:56 15/01/2026 GMT			5-day change	1st Jan Change
66.76 ^USD	+1.30%		+2.54%	+0.39%

01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
01-12	Arrowhead Pharmaceuticals issues $700 million of 0.00% convertible notes due 2032 - SEC filing	RE

Duration

Period